Submitted abstractsGastrointestinal tumours, colorectal516P - Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial
Gastrointestinal tumours, colorectal
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2016 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.